NCT02420730 is a Phase 1 clinical trial of AGN-232411 in Healthy Volunteers, sponsored by Allergan.

Who is sponsoring NCT02420730?

NCT02420730 is sponsored by Allergan.

What drugs are being tested in NCT02420730?

Interventions in NCT02420730: AGN-232411, AGN-232411 Vehicle.

What condition does NCT02420730 study?

NCT02420730 studies Healthy Volunteers, Dry Eye Syndromes.

Is NCT02420730 still recruiting?

NCT02420730 is currently completed. Last updated 13 July 2016.

Last reviewed 2016-07-13 · How we verify

NCT02420730

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye

Completed Phase 1 Last updated 13 July 2016

What this trial tests

Phase 1 trial testing AGN-232411 in Healthy Volunteers in 77 participants. Completed in 1 March 2016.

Timeline

1 June 2015

Primary endpoint
1 March 2016

1 March 2016

Quick facts

Lead sponsor	Allergan
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	77
Start date	1 June 2015
Primary completion	1 March 2016
Estimated completion	1 March 2016
Sites	3 locations across United States

Drugs / interventions tested

AGN-232411 — full drug profile →
AGN-232411 Vehicle — full drug profile →

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →
Dry Eye Syndromes — all drugs for Dry Eye Syndromes →

Sponsor

Allergan — full company profile →

Who can join

18 and older, any sex, with Healthy Volunteers or Dry Eye Syndromes. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Percentage of Participants with Treatment Emergent Adverse Events (TEAEs)
Time frame: Up to 56 days

Sponsor's own description

This study will examine the safety, tolerability, and systemic pharmacokinetics of up to 3 different concentrations of AGN-232411 topical ophthalmic solution in healthy participants and participants with dry eye.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Allergan trials

Trials by the same sponsor.

NCT04609020 — Study to Evaluate Subject Satisfaction With Facial Appearance and Impact of Combined Facial Treatment · Phase 4 · completed
NCT05452070 — A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft · Phase 3 · completed
NCT05393089 — Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopi · Phase 2 · withdrawn
NCT05152576 — A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants Wi · Phase 2 · completed
NCT05088980 — Study to Assess Effectiveness and Adverse Events of JUVEDERM VOLBELLA With Lidocaine Injection in Correcting Infraorbita · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02420730 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Allergan
Last refreshed: 13 July 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02420730.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing